Table 5.
Univariate and multivariate analyses for malignant diseases relapse, DFS, and OS
| Variable | Relapse | DFS | OS | |||
|---|---|---|---|---|---|---|
| Univariable | Multivariable (HR) | Univariable | Multivariable (HR) | Univariable | Multivariable (HR) | |
| Male vs female | P = .773 | P = .925 | P = .747 | P = .727 | P = .422 | P = .475 |
| Patient age, >30 y old, ≤30 y old | P = .300 | P = .965 | P = .770 | P = .649 | P = .511 | P = .512 |
| Myelogenous vs lymphoid | P = .005 |
P = .004 (0.732) 95% CI: 0.592‐0.904 |
P = .086 |
P = .026 (0.824) 95% CI: 0.694‐0.978 |
P = .667 | P = .295 |
| Donor type | P = .041 | P = .021 | P = .080 | |||
| MSD vs HRD | P = .365 | P = .431 | P = .264 | |||
| MUD vs HRD | P = .113 | P = .733 | P = .147 | |||
| MSD vs MUD | P = .312 | P = .778 | P = .556 | |||
| CR vs non‐CR | P < .001 |
P < .001 (0.668) 95% CI: 0.536‐0.833 |
P < .001 |
P = .004 (0.765) 95% CI: 0.639‐0.916 |
P < .001 |
P < .001 (0.678) 95% CI: 0.554‐0.829 |
| PBSCs vs PBSCs + BM | P = .062 | P = .531 | P = .022 | P = .584 | P = .047 | P = 309 |
| HLA matched vs mismatched | P = .016 | P = .263 | P = .010 | P = .411 | P = .032 | P = 242 |
| ABO matched vs mismatched | P = .817 | P = .651 | P = .911 | P = .713 | P = .745 | P = 911 |
| Sex matched vs mismatched | P = .216 | P = .136 | P = .250 | P = .159 | P = .337 | P = 227 |
| ATG used vs non‐used | P = .705 | P = .958 | P = .263 | P = .706 | P = .083 | P = .190 |
| TBI uses vs non‐used | P < .001 | P = .798 | P = .001 | P = .795 | P < .001 | P = .214 |
| CMV viremia positive vs negative | P = .341 | P = .484 | P = .880 | P = .618 | P = .068 | P = .444 |
| aGVHD vs non‐aGVHD | P = .186 | P = .131 | P = .989 | P = .432 | P = .361 | P = .849 |
| cGVHD vs non‐cGVHD | P < .001 |
P < .001 (0.667) 95% CI: 0.532‐0.838 |
P < .001 |
P = .001 (0.738) 95% CI: 0.617‐0.883 |
P < .001 |
P < .001 (0.666) 95% CI: 0.540‐0.821 |
| AIHA vs non‐AIHA | P = .011 |
P = .049 (0.139) 95% CI: 0.020‐0.999 |
P = .003 |
P = .026 (0.275) 95% CI: 0.088‐0.856 |
P = .036 | P = .074 |
Abbreviations: aGVHD, acute graft vs host disease; AIHA, autoimmune hematological diseases; ATG, antithymocyte globulin; BM, bone marrow; cGVHD, chronic graft vs host disease; CI, confidence interval; CMV, cytomegalovirus; CR, complete remission; DFS, disease‐free survival; HLA, human leukocyte antigen; HR, hazard ratio; HRD, haploidentical‐related donor; MSD, matched sibling donor; MUD, matched unrelated donor; OS, overall survival; PBSCs, peripheral blood stem cells; TBI, total body irradiation.